Thousand Oaks, a rapidly growing Contract Development and Manufacturing Organization (CDMO) and cell culture biotechnology company, announced today that it has raised over RMB 400 million in its Series C Financing in March 2021. This round of financing was jointly led by China Venture Capital Fund and Hillhouse Capital, with participation from CDH Investments, Highlight Capital, China US Green Fund, and Trinity Capital, as well as existing shareholders including Goldstone Fund, CICC Capital, and Fosun Fund.

CEC Capital Group served as the exclusive financial advisor for Thousand Oaks in this transaction.